Clinical trials: Relapsed Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma (RRMM)
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use.
- Trial name
- NCT06479954
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Phase 2, Radiotherapy-Induced Immune Priming
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
- Conditions
- Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT07382739
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma.
- Trial name
- ECAR01 (NCT06961669)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Relapsed or Refractory Multiple Myeloma
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
This is a prospective long-term follow-up (LTFU) study to evaluate the long-term safety and survival benefit for patients who received at least one of CARsgen's GM T cell product in a clinical trial or as a commercially available…
- Trial name
- NCT06825845
- Testing
- Zevorcabtagene Autoleucel
- Volunteers
- 1,500 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.
- Conditions
- Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
- Trial name
- NCT06783816
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanxi Bethune Hospital
Relapsed/Refractory Multiple Myeloma
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.
- Trial name
- NCT03169361
- Testing
- Ixazomib
- Where
- Japan
- Volunteers
- 774 people
- Sponsor
- Takeda
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program in Spain between November…
- Trial name
- NCT05297240
- Testing
- Belantamab mafodotin
- Where
- 62 sites in Spain
- Volunteers
- 170 people
- Sponsor
- PETHEMA Foundation